Literature DB >> 10882825

Repeated dose study of sucralose tolerance in human subjects.

I M Baird1, N W Shephard, R J Merritt, G Hildick-Smith.   

Abstract

Two tolerance studies were conducted in healthy human adult volunteers. The first study was an ascending dose study conducted in eight subjects, in which sucralose was administered at doses of 1, 2. 5, 5 and 10mg/kg at 48-hour intervals and followed by daily dosing at 2mg/kg for 3 days and 5mg/kg for 4 days. In the second study, subjects consumed either sucralose (n=77) or fructose (50g/day) (n=31) twice daily in single blind fashion. Sucralose dosage levels were 125mg/day for weeks 1-3, 250mg/day during weeks 4-7, and 500mg/day during weeks 8-12. No adverse experiences or clinically detectable effects were attributable to sucralose in either study. Similarly, haematology, serum biochemistry, urinalysis and EKG tracings were unaffected by sucralose administration. In the 13-week study, serial slit lamp ophthalmologic examination performed in a random subset of the study groups revealed no changes. Fasting and 2-hour post-dosing blood sucralose concentrations obtained daily during week 12 of the study revealed no rising trend for blood sucralose. Sucralose was well tolerated by human volunteers in single doses up to 10mg/kg/day and repeated doses increasing to 5mg/kg/day for 13 weeks. Based on these studies and the extensive animal safety database, there is no indication that adverse effects on human health would occur from frequent or long-term exposure to sucralose at the maximum anticipated levels of intake.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882825     DOI: 10.1016/s0278-6915(00)00035-1

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  9 in total

1.  Plasma concentrations of sucralose in children and adults.

Authors:  Allison C Sylvetsky; Viviana Bauman; Jenny E Blau; H Martin Garraffo; Peter J Walter; Kristina I Rother
Journal:  Toxicol Environ Chem       Date:  2016-10-17       Impact factor: 1.437

2.  Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans.

Authors:  Jelle R Dalenberg; Barkha P Patel; Raphael Denis; Maria G Veldhuizen; Yuko Nakamura; Petra C Vinke; Serge Luquet; Dana M Small
Journal:  Cell Metab       Date:  2020-03-03       Impact factor: 27.287

Review 3.  Metabolic effects of non-nutritive sweeteners.

Authors:  M Yanina Pepino
Journal:  Physiol Behav       Date:  2015-06-19

Review 4.  Sucralose and Cardiometabolic Health: Current Understanding from Receptors to Clinical Investigations.

Authors:  Sydney Risdon; Sylvain Battault; Alonso Romo-Romo; Matthieu Roustit; Loic Briand; Grégory Meyer; Paloma Almeda-Valdes; Guillaume Walther
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

5.  Non-caloric sweetener provides magnetic resonance imaging contrast for cancer detection.

Authors:  Puneet Bagga; Mohammad Haris; Kevin D'Aquilla; Neil E Wilson; Francesco M Marincola; Mitchell D Schnall; Hari Hariharan; Ravinder Reddy
Journal:  J Transl Med       Date:  2017-05-30       Impact factor: 5.531

Review 6.  Nonnutritive Sweeteners in Weight Management and Chronic Disease: A Review.

Authors:  Allison C Sylvetsky; Kristina I Rother
Journal:  Obesity (Silver Spring)       Date:  2018-04       Impact factor: 5.002

Review 7.  Sucralose, a synthetic organochlorine sweetener: overview of biological issues.

Authors:  Susan S Schiffman; Kristina I Rother
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2013       Impact factor: 6.393

Review 8.  Sucralose Non-Carcinogenicity: A Review of the Scientific and Regulatory Rationale.

Authors:  Colin Berry; David Brusick; Samuel M Cohen; Jerry F Hardisty; V Lee Grotz; Gary M Williams
Journal:  Nutr Cancer       Date:  2016-09-21       Impact factor: 2.900

9.  Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies.

Authors:  Ingrid Toews; Szimonetta Lohner; Daniela Küllenberg de Gaudry; Harriet Sommer; Joerg J Meerpohl
Journal:  BMJ       Date:  2019-01-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.